Contraindications: Rossiaz Lab Primobolan 100mg/ml is contraindicated in individuals with known androgen sensitivity, active or suspected prostate pathology, elevated haematocrit above 52%, polycythaemia, hepatic impairment, or cardiovascular disease. Not for use in women of childbearing potential or adolescents under 21. Pregnancy and lactation are absolute contraindications.
Side Effects: Androgenic effects including accelerated scalp hair recession in genetically predisposed individuals, mild acne, and increased sebum production are the most commonly reported. Suppression of the hypothalamic-pituitary-gonadal axis occurs in a dose-dependent manner — expect measurable LH and FSH reduction within three to four weeks at bulking doses. Lipid-profile shifts (reduced HDL, moderately elevated LDL) have been documented in clinical androgenic use; cardiovascular risk accumulates with cycle duration and elevated caloric intake.
Monitoring: Run a full blood panel before the first injection establishing baseline haematocrit, lipid fractions, liver enzymes (ALT, AST), total testosterone, LH, FSH, and oestradiol. Repeat at weeks six and twelve of the bulk. HOMA-IR monitoring is advisable when combining Methenolone Enanthate with GH-axis compounds. Blood pressure measurement twice weekly is recommended throughout the caloric-surplus phase.
PCT: Initiate a SERM-based PCT protocol after allowing sufficient time for Methenolone Enanthate plasma concentrations to decline following the final injection. Clomiphene 50mg daily or Tamoxifen 20mg daily for four weeks represents the standard framework; restart LH and FSH bloodwork at week three of PCT to confirm gonadal recovery is progressing. Supporting natural testosterone production with HCG during the final two weeks of the cycle before PCT initiation is an option for longer bulk durations exceeding 14 weeks.